George Budwell

George Budwell

TMFGBudwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles





Is Dynavax Technologies a Buy?

Dynavax's stock surged higher in August. Can this small-cap biotech keep churning higher?





3 Top Biotech Stocks to Buy Right Now

Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.









3 Top Cannabis Stocks to Watch in August

Canopy Growth, Charlotte's Web Holdings, and HEXO Corp. are worth checking out this month. Here's why.